WebMar 24, 2024 · Incyte, which reported Jakafi revenue topping $2.4 billion last year, said it plans to meet with the FDA to determine appropriate next steps. Under a long-running collaboration, Incyte markets... WebApr 14, 2024 · Incyte stock opened at $75.33 on Wednesday. The company has a market cap of $16.80 billion, a P/E ratio of 49.56, a price-to-earnings-growth ratio of 3.21 and a beta of 0.73. Incyte has a 1-year low of $65.07 and a 1-year high of $86.29. The company has a fifty day simple moving average of $75.69 and a 200 day simple moving average of $76.88.
INCY Stock Forecast, Price & News (Incyte) - MarketBeat
WebApr 10, 2024 · Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was … WebJan 31, 2024 · In the last reported quarter, Incyte missed earnings by 16.67%. Shares of Incyte have risen 12.5% in the past year against the industry’s decline of 10.4%. Zacks Investment Research Image... pool valves and fittings
INCY Incyte Corp. Stock Price & News - WSJ
WebApr 10, 2024 · Incyte Stock (NASDAQ:INCY), Analyst Ratings, Price Targets, Predictions Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can... WebApr 15, 2024 · Incyte (NASDAQ:INCY - Get Rating) last announced its quarterly earnings results on Tuesday, February 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.59 by $0.03. Incyte had a net margin of 10.03% and a return on equity of 11.45%. The company had revenue of $926.70 million for … WebApr 6, 2024 · Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and … shared roofline